Skip To Main Content
Visit Patient Site

Visual Acuity Outcomes

Visual acuity gains equivalent to monthly injections with as few as 2 refills a year*†1,10

Observed mean BCVA change from baseline to week 96 in ARCHWAY‡10

Chart: Observed mean BCVA change from baseline to week 96

Average BCVA change over weeks 36 and 40 in ARCHWAY (primary endpoint)1

Infographic: Average BCVA over weeks 36 and 40 in ARCHWAY (primary endpoint)

*Visual acuity was decreased by 4 letters on average in the first postoperative month and 2 letters on average in the second postoperative month following initial implantation of SUSVIMO. Equivalence is defined in the protocol as the 95% CI for the difference being within + or - 4.5 letters.

†Supplemental treatment with 0.5 mg (10 mg/mL) intravitreal ranibizumab injections was available at Weeks 16, 20, 40, 44, 64, 68, 88, and 92, if clinically necessary. In the first 24 weeks, 1.6% of patients assessed for supplemental treatment received 1 or more supplemental treatment(s). In the following 24 weeks, 5.4% of patients assessed for supplemental treatments received 1 or more supplemental treatment(s).

‡BCVA over time until Week 96 were prespecified secondary endpoint; multiplicity adjusted 95% CI.

Vision outcomes observed over 5 years in the PORTAL extension trial*13

Mean change from baseline in BCVA over 5 years13

Chart: Mean change from baseline in BCVA over 5 years

PORTAL is an extension study designed to evaluate long-term safety and tolerability of SUSVIMO in nAMD13

This 5 year PORTAL analysis population included patients from the Phase 2 LADDER trial that were:13

  • Treated with SUSVIMO PRN and rolled over to SUSVIMO 100 mg/mL Q24W
  • Previously treated with IVT ranibizumab Q4W and rolled over to SUSVIMO 100 mg/mL Q24W

Average BCVA over 5 years in PORTAL:13

Infographic: Average BCVA over 5 years in PORTAL

*Baseline is defined as the last assessment on or before the first study treatment in LADDER. Target visit dates are spaced 30 days apart in Ladder assessments and 56 days apart for PORTAL assessments. Last observation carried forward was used for intermittent missing values during PORTAL to correct for the difference in visit schedules. The bars represent multiplicity-adjusted 95% CI.

Anatomy

BCVA=best corrected visual acuity; ETDRS=Early Treatment Diabetic Retinopathy Study; IVT=intravitreal; nAMD=neovascular (wet) age-related macular degeneration; PRN=pro re nata; Q4W=every-4-week dosing; Q24W=every-24-week dosing.

Important Safety Information

Indication

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor medication.

WARNING: ENDOPHTHALMITIS

The SUSVIMO implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosions may reduce the risk of endophthalmitis. In clinical trials, 2.0% of patients receiving a ranibizumab implant experienced at least 1 episode of endophthalmitis.

Contraindications

SUSVIMO is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or hypersensitivity to ranibizumab products or any of the excipients in SUSVIMO.

Warnings and Precautions

The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, and conjunctival blebs. Patients should be instructed to report any signs or symptoms that could be associated with these events without delay. In some cases, these events can present asymptomatically. The implant and the tissue overlying the implant flange should be monitored routinely following the implant insertion and refill-exchange procedures to permit early medical or surgical intervention as necessary. Special precautions need to be taken when handling SUSVIMO components.

Endophthalmitis

In the active comparator period of controlled clinical trials, the ranibizumab implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab (1.7% in the SUSVIMO arm vs 0.5% in the intravitreal arm). When including extension phases of clinical trials, 2.0% (11/555) of patients receiving the ranibizumab implant experienced an episode of endophthalmitis. Reports occurred between day 5 and day 853, with a median of day 173. Many, but not all, of the cases of endophthalmitis reported a preceding or concurrent conjunctival retraction or erosion event.

Endophthalmitis should be treated promptly in an effort to reduce the risk of vision loss and maximize recovery. The SUSVIMO dose (refill-exchange) should be delayed until resolution of endophthalmitis.

Patients should not have an active or suspected ocular or periocular infection or severe systemic infection at the time of any SUSVIMO implant or refill procedure. Appropriate intraoperative handling followed by secure closure of the conjunctiva and Tenon’s capsule, and early detection and surgical repair of conjunctival erosions or retractions may reduce the risk of endophthalmitis.

Rhegmatogenous Retinal Detachment

Rhegmatogenous retinal detachments have occurred in clinical trials of SUSVIMO and may result in vision loss. Rhegmatogenous retinal detachments should be promptly treated with an intervention (e.g., pneumatic retinopexy, vitrectomy, or laser photocoagulation). The SUSVIMO dose (refill-exchange) should be delayed in the presence of a retinal detachment or retinal break.

Careful evaluation of the retinal periphery is recommended to be performed, and any suspected areas of abnormal vitreo-retinal adhesion or retinal breaks should be treated before inserting the implant in the eye.

Implant Dislocation

In clinical trials, the device dislocated/subluxated into the vitreous cavity or extended outside the vitreous cavity into or beyond the subconjunctival space. Device dislocation requires urgent surgical intervention. Strict adherence to the scleral incision length and appropriate targeting of the pars plana during laser ablation may reduce the risk of implant dislocation.

Septum Dislodgement

In clinical trials, a type of implant damage where the septum has dislodged into the implant body has been reported. Perform a dilated slit lamp exam and/or dilated indirect ophthalmoscopy to inspect the implant in the vitreous cavity through the pupil prior to and after the refill-exchange procedure to identify if septum dislodgement has occurred. Discontinue treatment with SUSVIMO following septum dislodgement and consider implant removal should the benefit of the removal procedure outweigh the risk.

Appropriate handling and insertion of the refill needle into the septum (avoid twisting and/or rotation) is required to minimize the risk of septum dislodgement.

Vitreous Hemorrhage

Vitreous hemorrhages may result in temporary vision loss. Vitrectomy may be needed in the case of a nonclearing vitreous hemorrhage.

In clinical trials of SUSVIMO, including extension phases, vitreous hemorrhages were reported in 5.2% (23/443) of patients receiving SUSVIMO. The majority of these hemorrhages occurred within the first postoperative month following surgical implantation, and the majority of vitreous hemorrhages resolved spontaneously. Patients on antithrombotic medication (e.g., oral anticoagulants, aspirin, nonsteroidal anti-inflammatory drugs) may be at increased risk of vitreous hemorrhage. Antithrombotic medications are recommended to be temporarily interrupted prior to the implant insertion procedure. The SUSVIMO dose (refill-exchange) should be delayed in the event of sight-threatening vitreous hemorrhage. The use of pars plana laser ablation and scleral cauterization should be performed to reduce the risk of vitreous hemorrhage.

Conjunctival Erosion or Retraction

A conjunctival erosion is a full-thickness degradation or breakdown of the conjunctiva in the area of the implant flange. A conjunctival retraction is a recession or opening of the limbal and/or radial peritomy. Conjunctival erosions or retractions have been associated with an increased risk of endophthalmitis, especially if the implant becomes exposed. Surgical intervention (e.g., conjunctival/Tenon’s capsule repair) is recommended to be performed in cases of conjunctival erosion or retraction with or without exposure of the implant flange.

In clinical trials of SUSVIMO, including extension phases, 3.6% (16/443) of patients receiving SUSVIMO reported conjunctival erosion and 1.6% (7/443) of patients receiving SUSVIMO reported conjunctival retraction in the study eye.

Appropriate intraoperative handling of the conjunctiva and Tenon’s capsule to preserve tissue integrity and secure closure of peritomy while ensuring placement of sutures away from implant edge may reduce the risk of conjunctival erosion or retraction. The implant and the tissue overlying the implant flange should be monitored routinely following the implant insertion.

Conjunctival Bleb

A conjunctival bleb is an encapsulated elevation of the conjunctiva above the implant flange, which may be secondary to subconjunctival thickening or fluid. Conjunctival blebs may require surgical management to avoid further complications, especially if the implant septum is no longer identifiable due to the conjunctival bleb.

In clinical trials of SUSVIMO, including extension phases, 5.9% (26/443) of patients receiving SUSVIMO reported conjunctival bleb/conjunctival filtering bleb leak in the study eye. Strict adherence to the scleral incision length, appropriate intraoperative handling of the conjunctiva and Tenon’s capsule to preserve tissue integrity and secure closure of peritomy, and proper seating of the refill needle during refill-exchange procedures may reduce the risk of conjunctival bleb.

Postoperative Decrease in Visual Acuity

Visual acuity was decreased by an average of 4 letters in the first postoperative month and an average of 2 letters in the second postoperative month following initial implantation of SUSVIMO.

Air Bubbles Causing Improper Filling of the Implant

Minimize air bubbles within the implant reservoir, as they may cause slower drug release. During the initial fill procedure, if an air bubble is present, it must be no larger than ⅓ of the widest diameter of the implant. If excess air is observed after initial fill, do not use the implant. During the refill-exchange procedure, if excess air is present in the syringe and needle, do not use the syringe and needle. If excess air bubbles are observed after the refill-exchange procedure, consider repeating the refill-exchange procedure.

Deflection of the Implant

Use caution when performing ophthalmic procedures that may cause deflection of the implant and subsequent injury. For example, B-scan ophthalmic ultrasound, scleral depression, or gonioscopy.

Adverse Reactions

In the nAMD Archway study following the SUSVIMO initial fill and implant insertion, refill, and implant removal (if necessary) procedures up to week 40, the most common (≥10%) adverse reactions up to week 40 were conjunctival hemorrhage (72%), conjunctival hyperemia (26%), iritis (23%), and eye pain (10%).

Females and Males of Reproductive Potential

Females of reproductive potential should use effective contraception during treatment with SUSVIMO and for at least 12 months after the last dose of SUSVIMO. No studies on the effects of ranibizumab on fertility have been conducted and it is not known whether ranibizumab can affect reproduction capacity. Based on the anti-VEGF mechanism of action for ranibizumab, treatment with SUSVIMO may pose a risk to reproductive capacity.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including BOXED WARNING.

Back to Top

    • SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.

      SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.

    • Adam M, et al. Presented at Association for Research in Vision and Ophthalmology (ARVO) 2022. May 01-May 06 2022.

      Adam M, et al. Presented at Association for Research in Vision and Ophthalmology (ARVO) 2022. May 01-May 06 2022.

    • SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.

      SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.

    • Chakravarthy U et al. Eye . 2021 Nov;35(11):2983-2990.

      Chakravarthy U et al. Eye . 2021 Nov;35(11):2983-2990.

    • Monés, J et al. Ophthalmologica. 2020: 243(1), 1-8.

      Monés, J et al. Ophthalmologica. 2020: 243(1), 1-8.

    • Ciulla TA et al. Opthalmol Retina. 2018;2(7)645-653.

      Ciulla TA et al. Opthalmol Retina. 2018;2(7)645-653.

    • Campochiaro PA  et al. Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022, February 11-12, 2022.

      Campochiaro PA  et al. Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022, February 11-12, 2022.

    • Ranade SV,  et al. Drug Delivery. 2022;29(1):1326-1334.

      Ranade SV,  et al. Drug Delivery. 2022;29(1):1326-1334.

    • Monés J, et al. Presented at: 21st EURETINA Congress, September 9-12, 2021.

      Monés J, et al. Presented at: 21st EURETINA Congress, September 9-12, 2021.

    • Regillo C, et al. Am J Ophthalmol. 2023;130(7):735-747.

      Regillo C, et al. Am J Ophthalmol. 2023;130(7):735-747.

    • Holekamp NM, et al. Opthalmol. 2022;129(3):295-307.91

      Holekamp NM, et al. Opthalmol. 2022;129(3):295-307.91

    • ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934

      ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934

    • Massop D, et al. Presented at the American Society of Retina Specialists Annual Meeting. July 28–August 1, 2023.

      Massop D, et al. Presented at the American Society of Retina Specialists Annual Meeting. July 28–August 1, 2023.

    • Chang MA, et al. JAMA ophthalmology. 2022; 140(8), 771-778.

      Chang MA, et al. JAMA ophthalmology. 2022; 140(8), 771-778.

    • Boulanger-Scemama E et al. J Fr Ophtalmol. 2015;38:620–627.

      Boulanger-Scemama E et al. J Fr Ophtalmol. 2015;38:620–627.

    • Senra H et al. Am J Ophthalmol. 2017;177:213-224.

      Senra H et al. Am J Ophthalmol. 2017;177:213-224.

    • Awh C, et al. Ophthalmol Retina. 2022;6(11),1028-1043.

      Awh C, et al. Ophthalmol Retina. 2022;6(11),1028-1043.